142 related articles for article (PubMed ID: 37070141)
1. Studentized permutation method for comparing two restricted mean survival times with small sample from randomized trials.
Ditzhaus M; Yu M; Xu J
Stat Med; 2023 Jun; 42(13):2226-2240. PubMed ID: 37070141
[TBL] [Abstract][Full Text] [Related]
2. On permutation tests for comparing restricted mean survival time with small sample from randomized trials.
Horiguchi M; Uno H
Stat Med; 2020 Sep; 39(20):2655-2670. PubMed ID: 32432805
[TBL] [Abstract][Full Text] [Related]
3. RMST-based multiple contrast tests in general factorial designs.
Munko M; Ditzhaus M; Dobler D; Genuneit J
Stat Med; 2024 May; 43(10):1849-1866. PubMed ID: 38402907
[TBL] [Abstract][Full Text] [Related]
4. Design of non-inferiority randomized trials using the difference in restricted mean survival times.
Weir IR; Trinquart L
Clin Trials; 2018 Oct; 15(5):499-508. PubMed ID: 30074407
[TBL] [Abstract][Full Text] [Related]
5. Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio.
Pak K; Uno H; Kim DH; Tian L; Kane RC; Takeuchi M; Fu H; Claggett B; Wei LJ
JAMA Oncol; 2017 Dec; 3(12):1692-1696. PubMed ID: 28975263
[TBL] [Abstract][Full Text] [Related]
6. Restricted mean survival time to estimate an intervention effect in a cluster randomized trial.
Vilain-Abraham FL; Tavernier E; Dantan E; Desmée S; Caille A
Stat Methods Med Res; 2023 Oct; 32(10):2016-2032. PubMed ID: 37559486
[TBL] [Abstract][Full Text] [Related]
7. Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study.
Zhao L; Tian L; Uno H; Solomon SD; Pfeffer MA; Schindler JS; Wei LJ
Clin Trials; 2012 Oct; 9(5):570-7. PubMed ID: 22914867
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point.
Huang B; Kuan PF
Pharm Stat; 2018 May; 17(3):202-213. PubMed ID: 29282880
[TBL] [Abstract][Full Text] [Related]
9. A comparison of different population-level summary measures for randomised trials with time-to-event outcomes, with a focus on non-inferiority trials.
Quartagno M; Morris TP; Gilbert DC; Langley RE; Nankivell MG; Parmar MK; White IR
Clin Trials; 2023 Dec; 20(6):594-602. PubMed ID: 37337728
[TBL] [Abstract][Full Text] [Related]
10. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome.
Royston P; Parmar MK
BMC Med Res Methodol; 2013 Dec; 13():152. PubMed ID: 24314264
[TBL] [Abstract][Full Text] [Related]
11. A studentized permutation test for three-arm trials in the 'gold standard' design.
Mütze T; Konietschke F; Munk A; Friede T
Stat Med; 2017 Mar; 36(6):883-898. PubMed ID: 27859506
[TBL] [Abstract][Full Text] [Related]
12. Restricted mean survival time as a summary measure of time-to-event outcome.
Hasegawa T; Misawa S; Nakagawa S; Tanaka S; Tanase T; Ugai H; Wakana A; Yodo Y; Tsuchiya S; Suganami H;
Pharm Stat; 2020 Jul; 19(4):436-453. PubMed ID: 32072769
[TBL] [Abstract][Full Text] [Related]
13. Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated.
Royston P; Parmar MK
BMC Med Res Methodol; 2016 Feb; 16():16. PubMed ID: 26869168
[TBL] [Abstract][Full Text] [Related]
14. Are restricted mean survival time methods especially useful for noninferiority trials?
Freidlin B; Hu C; Korn EL
Clin Trials; 2021 Apr; 18(2):188-196. PubMed ID: 33626896
[TBL] [Abstract][Full Text] [Related]
15. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
Horiguchi M; Hassett MJ; Uno H
Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
[TBL] [Abstract][Full Text] [Related]
16. Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer.
Liang F; Zhang S; Wang Q; Li W
Ann Oncol; 2018 May; 29(5):1320-1324. PubMed ID: 29788167
[TBL] [Abstract][Full Text] [Related]
17. Generalized fiducial inference for the restricted mean survival time.
Bebu I; Diao G; Hamasaki T
Stat Methods Med Res; 2023 May; 32(5):1010-1020. PubMed ID: 36974594
[TBL] [Abstract][Full Text] [Related]
18. Cancer Biology and Survival Analysis in Cancer Trials: Restricted Mean Survival Time Analysis versus Hazard Ratios.
A'Hern RP
Clin Oncol (R Coll Radiol); 2018 Sep; 30(9):e75-e80. PubMed ID: 29776805
[TBL] [Abstract][Full Text] [Related]
19. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
20. An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect.
Royston P; Parmar MK
Trials; 2014 Aug; 15():314. PubMed ID: 25098243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
